Thermo Fisher sees robust 2025 profit on improved demand for its tools and services (updated)

Sartorius AG

30/01/2025 16:20

(Rewrites paragraph 1, adds 2025 profit forecast in paragraph
6, adds graphic)
       Jan 30 (Reuters) - Thermo Fisher Scientific  TMO.N  on
Thursday forecast annual profit above Wall Street estimates,
banking on improved demand for its products and services used in
developing therapies, sending its shares up 6.5% in morning
trading. 
    The company also beat estimates for fourth-quarter profit
and revenue, boosted by strong demand for its analytical
instruments segment.
    Contract drug manufacturers witnessed reduced spending from
biotech clients in the past two years, but recent interest rate
cuts could improve the funding environment for biotechs as
borrowing costs might ease.
    However, some life sciences firms such as rival Danaher
 DHR.N  have indicated that despite the rate cuts smaller
biotech clients are still cautious with their investments.
    Earlier this week, Franco-German peer Sartorius  SATG.DE 
reported preliminary annual results that beat expectations and
posted a 23.1% rise in fourth-quarter orders for its key
Bioprocess Solutions division, lifting shares of life sciences
firms such as Thermo Fisher. 
    The medical device maker forecast 2025 adjusted profit in
the range of $23.10 to $23.50 per share, while analysts were
expecting $23.10 per share. 
    On an adjusted basis, Thermo Fisher earned a profit of $6.10
per share for the quarter ended Dec. 31, beating analysts'
estimates of $5.94 per share, as per data compiled by LSEG.  
    The Waltham Massachusetts-based company's revenue rose 5% to
$11.40 billion, ahead of estimates of $11.28 billion.
        
  

    <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Thermo Fisher's fourth-quarter segment sales    https://reut.rs/4jCBEt1
    ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
 (Reporting by Sneha S K in Bengaluru; Editing by Shailesh
Kuber)
 ((Sneha.SK@thomsonreuters.com;))